Expert Interview
Prescribing Update on Iovance’s Amtagvi (lifileucel) for Melanoma
Ticker(s): IOVA, REPLInstitution: Dana Farber Cancer Institute
- Clinical Director of the Melanoma Disease Center, Director of Clinical Sciences for the Center for Immuno-Oncology, and Senior Physician at Dana Farber Cancer Institute
- Treats 50 patients per month with advanced unresectable or metastatic melanoma
- Clinical Interest and expertise in immunotherapy and melanoma and is the PI for several Phase 1 studies in melanoma.
Have you prescribed or referred any patients for treatment with Amtagvi (lifileucel) since its approval for advanced melanoma?
Added By: sara_adminHow would you compare Amtagvi’s clinical profile—particularly its efficacy and safety—to existing options like PD-1 inhibitors, CTLA-4 therapies, or combination regimens?
Added By: sara_adminHas REPL's recent delay or clinical setback affected your perception of the competitive landscape for melanoma?
Added By: sara_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
